alendar months. That means building a milestone-based budget, forecasting burn under several scenarios, managing contract research spend closely, layering in non-dilutive funding such as grants and R&D tax credits, and starting the next raise well before cash gets tight. In most industries, running low on cash is a problem. In biotech, it can end a program that took years to build. A promising compound, a platform technology or a diagnostic can lose its
https://k38consulting.com/biotech-cfo-services/
fractional CFO for biotech companies
momentum simply because the money ran out a few months before the data that would have unlocked the next round. Timelines slip, experiments fail and regulatory steps take longer than planned, yet the burn continues every month. That reality is why many life science founders bring in a fractional CFO for biotech companies long before they could justify a full-time finance executive. The goal is simple but demanding: make every dollar of investor capital carry the company as far as possible toward value-creating milestones. This guide covers the cash planning practices that give biotech startups the most room to operate between funding rounds. Why Biotech Cash Planning Is Different A software company can often cut spending, change pricing or find revenue quickly. Most early-stage biotech companies cannot. They typically have little or no revenue, long development cycles and costs that are hard to pause without damaging the science. Several factors make biotech cash planning uniquely challenging: ● Binary outcomes. A study result can dramatically change the company's valuation, direction or funding options. ● Lumpy spending. Large payments for contract research, manufacturing runs or clinical activities arrive in bursts rather than evenly. ● Long lead times. Ordering materials, securing lab space or booking a contract research organization (CRO) can take months. ● Investor expectations tied to data. The next round usually depends on hitting a specific scientific or regulatory milestone. ● Specialized talent. Scientific staff are expensive and hard to replace, so headcount cuts carry real risk. Because of these pressures, a standard annual budget is rarely enough. Biotech companies need a plan that connects spending directly to the milestones that will drive the next financing. Build the Budget Around Milestones Definition: A milestone-based budget organizes spending by the scientific, clinical or regulatory achievements the company is working toward, such as completing IND-enabling studies, generating proof-of-concept data or finishing a first-in-human trial, rather than by department alone. This approach answers the question investors care about most: how much money does it take to reach the next inflection point? To build one: 1. List the milestones that will support the next raise. Be specific about what data or approvals are needed. 2. Map every activity required to reach each milestone, including studies, materials, manufacturing, regulatory work and staffing. 3. Estimate costs and timing for each activity, with input from scientific leadership and vendors. 4. Add a realistic buffer. Experiments often need repeating, and timelines rarely run shorter than planned. 5. Identify which spending is essential and which can wait. This becomes your playbook if cash gets tight. A milestone budget also makes board conversations easier. Instead of debating line items, leadership can discuss whether the company is on track to hit the data that matters. Forecast Burn Under More Than One Scenario A single forecast gives a false sense of certainty. Biotech companies benefit from modeling several versions of the future. Scenario Key Assumptions How It Is Used Base case Milestones hit on the current timeline and budget Day-to-day planning and investor updates Delay case Key studies take 3 to 6 months longer than planned Tests whether runway survives common setbacks Lean case Non-essential programs paused, hiring frozen Shows how far cash can stretch if needed Upside case Early data, partnership or grant arrives sooner Guides decisions on accelerating programs Each scenario should show monthly cash balance, burn rate and the date cash falls below a minimum safety level. Reviewing these monthly allows leadership to spot trouble early and adjust before options disappear. Companies that work with experienced cash flow management consulting partners often use rolling forecasts that update every month with actual results, so the runway estimate always reflects reality rather than the assumptions made at the last raise. Control the Largest Cost Drivers In many biotech startups, a handful of categories make up most of the burn. Small improvements in these areas can add months of runway. Contract research and manufacturing. CROs and contract manufacturers often represent a major share of spending. Review contracts carefully for payment schedules, change order terms and cancellation provisions. Tie payments to deliverables where possible, and track work performed against amounts paid so the company does not prepay far ahead of progress. Headcount. Salaries and benefits add up quickly. Consider whether some specialized work can be handled by consultants or contract scientists until a program proves out. Lab space and equipment. Shared lab facilities, incubators and equipment leasing can reduce large upfront commitments. Buying expensive equipment too early ties up cash that may be needed for experiments. Materials and supplies. Reagents, cell lines and specialty materials can carry long lead times and high costs. Better purchasing coordination helps avoid rush fees and waste. Accruals. Because research work often happens before invoices arrive, accurate accruals are essential. Without them, financial statements can understate spending, and the company may believe it has more runway than it actually does. Layer In Non-Dilutive Funding Every dollar that does not come from selling equity helps protect founders and early investors from dilution. Biotech companies have several options worth exploring. Government grants. Programs such as the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards, along with NIH and other agency grants, can fund specific research programs. Grants often come with detailed compliance and reporting requirements, so strong accounting controls matter. R&D tax credits. Research into new compounds, therapies, diagnostics and platform technologies often qualifies for the federal research credit. Working with a partner that offers rd tax credit consulting helps identify qualifying wages, supplies and contract research costs. Qualified small businesses that are not yet profitable may be able to apply the credit against payroll taxes, turning it into near-term cash. Note that research funded by grants or other parties may be treated differently when calculating the credit, so the two should be planned together. Strategic partnerships. Licensing deals, research collaborations and co-development agreements can bring upfront payments and milestone fees while validating the science. Venture debt. For companies with strong investor backing, venture debt can extend runway between equity rounds. It carries repayment obligations and covenants, so it should be modeled carefully before signing. Protect the Cash You Already Have Runway is not only about spending less. It is also about managing the money on hand wisely. ● Keep a clear minimum cash threshold that triggers action, such as starting a raise or activating the lean plan. ● Spread deposits thoughtfully and review bank relationships and deposit coverage, since concentration can create risk. ● Invest idle cash conservatively in liquid, low-risk options aligned with the company's investment policy. ● Set approval limits for spending so large commitments get proper review. ● Report cash position to the board regularly with a consistent format that shows actual results against the plan. Start the Next Raise Before You Need It One of the most common mistakes in biotech is waiting too long to raise. Fundraising frequently takes six months or more, and investors are more cautious when a company is visibly close to running out of cash. A practical rule is to begin preparing well before the company reaches its minimum runway threshold, ideally while there is still enough cash to reach the next milestone even if the round takes longer than expected. Preparation includes updating the financial model, organizing the data room, cleaning up accruals and cap table records, and preparing a clear use-of-funds plan tied to upcoming milestones. Inside K-38 Consulting's Approach to Biotech Finance K-38 Consulting, a Raleigh, North Carolina based finance firm founded by Dallas Alford IV, CPA, provides dedicated CFO support for biotech startups alongside its work with startups and midsize businesses across the United States. The firm's model pairs each client with a finance team that typically includes both a controller and a CFO. The controller manages accurate books, research accruals and a dependable monthly close, while the CFO focuses on runway planning, milestone budgeting, scenario forecasting, grant and funding management, and fundraising strategy. For biotech founders, that means scientific leadership can stay focused on the research while the finance team keeps the cash plan aligned with it. Because K-38 Consulting also offers R&D tax credit services, biotech clients can connect non-dilutive funding directly to their runway plans rather than treating tax credits as an afterthought. The team works with established platforms such as QuickBooks and NetSuite and uses web-based forecasting tools that give leadership a current view of burn and cash position. According to the firm, many businesses lose 10 to 15 hours a month to manual accounting work, so automation is part of how it sets up client finance operations. Client results reflect that focus. Dover Therapeutics, a biotech startup, has credited K-38 Consulting with helping it optimize financial operations, improve cash flow and strengthen business processes, and with providing the strategic insight and forecasting tools that supported its decisions, funding efforts and growth. K-38 Consulting serves clients in markets including Raleigh, Charlotte, Atlanta, Tampa, Miami, Austin, New York City, Chicago, San Francisco, San Jose and Los Angeles, several of which are major life science hubs. Biotech founders can book a free 30-minute strategy session with the founder to review their runway, funding plans and financial readiness for the next round. Runway Stress Test: Eight Questions for Your Leadership Team Work through these with your team and board: 1. Do we know exactly how much cash is needed to reach the next value-creating milestone? 2. Does our forecast include a delay scenario, and does runway survive it? 3. Are research accruals recorded accurately each month? 4. Are CRO and manufacturing payments tied to deliverables? 5. Have we reviewed eligibility for the R&D tax credit and payroll tax offset? 6. Are we pursuing grants or partnerships that fit our programs? 7. Do we have a defined minimum cash threshold and a lean-case plan? 8. When do we need to start fundraising to close before that threshold? If any answer is uncertain, that is the place to focus next. Biotech Runway Questions, Answered How much runway should a biotech startup keep after a raise? Many companies aim to raise enough to reach the next major milestone with additional buffer for delays. The right amount depends on the program, but planning for setbacks is essential. Can a pre-revenue biotech company claim the R&D tax credit? Potentially. Qualified small businesses may be able to apply the credit against payroll taxes even without income tax liability. Eligibility should be reviewed with an advisor. Why are research accruals so important? Research work is often performed before invoices arrive. Without accurate accruals, financial statements understate spending and runway can look longer than it really is. When should a biotech startup bring in a CFO? Many companies benefit from part-time or outsourced CFO support early, particularly before a priced round, a major grant application or the start of expensive preclinical or clinical work. Buying Time for the Science In biotech, time is often the most valuable resource a company has, and cash is what buys it. Founders who budget around milestones, forecast honestly, control their largest costs and pursue non-dilutive funding give their science the best possible chance to reach the data that matters. With an experienced finance partner like K-38 Consulting managing the numbers, biotech teams can extend their runway, raise from a position of str